Tonix Pharmaceuticals
(NASDAQ:TNXP)
Tonix Pharmaceuticals Holding Corp. - Common Stock is expected to split Monday, August 15, 2022 with a ratio of 1:5
Tonix Pharmaceuticals Holding Corp. - Common Stock recently split on Friday, August 12, 2022 with a ratio of 1:3
$1.40
0.03[2.19%]
At close: Aug 12
$1.41
0.0100[0.71%]
After Hours: 6:10PM EDT
Day High/Low1.36 - 1.43
52 Week High/Low0.09 - 4.79
Open / Close1.39 / 1.4
Float / Outstanding43M / 43.1M
Vol / Avg.2.7M / 13.9M
Mkt Cap60.3M
P/E-
50d Avg. Price1.71
Div / Yield-
Payout Ratio-
EPS-1.22
Total Float43M

Tonix Pharmaceuticals (NASDAQ:TNXP), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$4.00

Lowest Price Target1

$4.00

Consensus Price Target1

$48.48

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
3661511

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Deutsche Bank
  • Oppenheimer
  • JP Morgan
  • Piper Sandler

1calculated from analyst ratings published within the last 6 months

Analyst Ratings for Tonix Pharmaceuticals

All Ratings (0)

Upgrades (0)

Downgrades (0)

Initiations (0)

date
Upside/Downside
Analyst Firm
Price Target Change
Rating Change
Previous / Current Rating
Get Alert

Tonix Pharmaceuticals Questions & Answers

Q
What is the target price for Tonix Pharmaceuticals (TNXP)?
A

The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Cantor Fitzgerald on August 12, 2022. The analyst firm set a price target for $4.00 expecting TNXP to rise to within 12 months (a possible 185.71% upside). 100 analyst firms have reported ratings in the last year.

Q
What is the most recent analyst rating for Tonix Pharmaceuticals (TNXP)?
A

The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Cantor Fitzgerald, and Tonix Pharmaceuticals initiated their overweight rating.

Q
When is the next analyst rating going to be posted or updated for Tonix Pharmaceuticals (TNXP)?
A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on August 12, 2022 so you should expect the next rating to be made available sometime around August 12, 2023.

Q
Is the Analyst Rating Tonix Pharmaceuticals (TNXP) correct?
A

While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a initiated with a price target of $0.00 to $4.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $1.40, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.